Safety and Effectiveness of NY-ESO-1 TCR-T Cell Therapy in Adults with Advanced Soft Tissue Sarcoma

What this Trial Is About

Researchers are evaluating the safety and effectiveness of NY-ESO-1 TCR-T cell therapy in adults with advanced soft tissue sarcoma, a type of solid tumor that is diverse and challenging to treat. This study focuses on patients whose cancer has progressed after first-line treatments, as there is currently no standard second-line treatment. NY-ESO-1, a protein highly present in these tumors, is targeted by this new therapy. Participants will receive NY-ESO-1 TCR-T treatment, a biological therapy designed to target cancer cells expressing the NY-ESO-1 protein. The study involves a treatment group receiving this therapy. Patients must meet specific criteria including tumor expression of NY-ESO-1 and certain immune system characteristics. No antibody drugs are allowed within two weeks before receiving cell therapy. During the study, participants will be closely monitored for adverse events from the time of infusion up to 30 days afterward. Researchers will assess tumor response up to two years after admission. Evaluations include physical exams, blood tests, and imaging to measure treatment effects and safety. The study aims to ensure participants have no severe contraindications and an expected survival of more than three months, with overall participation lasting up to two years or more.

Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma